NCT06778902View on ClinicalTrials.gov

AZA Combined with R-GemOx for Elderly DLBCL Patients

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

February 1, 2025

Primary Completion Date

January 1, 2028

Study Completion Date

January 1, 2028

Conditions
DLBCL - Diffuse Large B Cell Lymphoma
Interventions
DRUG

azacytidine

Azacytidine: 75mg/m2, d1-d5

DRUG

R-GemOx

Rituximab: 375mg/m2, d6; Gemcitabine: 1g/m2, d7 Oxaliplatin: 100mg/m2, d7

Trial Locations (1)

400000

Daping Hospital, Third Military Medical University (Army Medical University), Chongqing

All Listed Sponsors
lead

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

OTHER